The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the granting of conditional marketing authorization of Tepkinly (epcoritamab), a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, after two or more lines of systemic therapy.
The National Cancer Institute approved the following clinical research studies last month.
Cancer centers that continue to experience pandemic-induced shortages in staffing their clinical research enterprise may soon be able to rely on support from NCI’s Virtual Clinical Trials Office to open studies and accrue patients.
Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research.
The NCI Board of Scientific Advisors approved five new concepts and 17 reissue concepts at a joint meeting of the BSA and the National Cancer Advisory Board June 11-12.
The University of Texas MD Anderson Cancer Center and Rice University formed the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis, and treatment.
The Snyder estate, now being sold by ACS. Source: Google, ©2024 AirbusThe American Cancer Society is selling the 25,000 square-foot mansion that was donated to the society by former Washington Commanders owner Dan Snyder and his wife Tanya Snyder, a breast cancer survivor, in March (The Cancer Letter, March 29, 2024).
Vivek S. Kavadi was named CEO of the American Society for Radiation Oncology. He will succeed Laura Thevenot, who has led the organization since 2002.
Miguel Villalona Calero was named deputy director of the University of California, Irvine Chao Family Comprehensive Cancer Center and division chief for hematology/oncology. He will start on July 8.
